Zobrazeno 1 - 10
of 58
pro vyhledávání: ''
Autor:
Cesare Gridelli, Yuichiro Ohe, Jaafar Bennouna, Ashis Das-Gupta, Nick Thatcher, Margarita Donica, Francesco Grossi, Matt Truman, Konstantinos N. Syrigos, Javier de Castro Carpeño, Frank Griesinger, Anne-Marie C. Dingemans, Corey J. Langer, Vlatka Smoljanovic
Publikováno v:
JAMA Oncology, 4(12):183486. American Medical Association
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Importance Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond p
Autor:
Fred Saad, Ola Lindén, Clemens Kratochwil, Val Lewington, Jae H. Park, Chris Parker, Moshe Yair Levy, Neal D. Shore, Walter Noordzij
Publikováno v:
JAMA Oncology. 4:1765
IMPORTANCE Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types. OBSERVATIONS Theoretically, the high-ener
Autor:
Victoria L. Seewaldt
Publikováno v:
JAMA Oncology. 4:1668
Autor:
George W. Sledge, Anne O'Neill, Antonio C. Wolff, Donald W. Northfelt, Joseph A. Sparano, Chau T. Dang, Katherine Alpaugh, Kathy D. Miller
Publikováno v:
JAMA Oncology. 4:1700
Importance Late recurrence 5 or more years after diagnosis accounts for at least one-half of all cases of recurrent hormone receptor–positive breast cancer. Objective To determine whether the presence of circulating tumor cells (CTCs) in a peripher
Autor:
Brett Bell, James M. Metz, Kelly M. MacArthur, Timothy D. Solberg, Constantinos Koumenis, Brian C. Baumann, Chuan Zeng, Sravya Koduri, Carolyn Vachani, Ioannis I. Verginadis
Publikováno v:
JAMA Oncology. 4:1742
Importance Radiation dermatitis is common and often treated with topical therapy. Patients are typically advised to avoid topical agents for several hours before daily radiotherapy (RT) out of concern that topical agents might increase the radiation
Autor:
Charles J. Ryan, Michael J. Morris, Jason Summa, Lowell L. Hart, Nicole A. Schreiber, Justine Anderson, Ryan Dittamore, Howard I. Scher, Ajjai Alva, Hagop Youssoufian, Edwin M. Posadas, Karen A. Autio, Matthew I. Milowsky, Ryon P. Graf, Jorge A. Garcia, Robert Dreicer
Publikováno v:
JAMA Oncology. 4:1344
Importance Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)–targeted nanoparticles is clinically effective, and the selective reduction of PSMA-positive circulating tumor cells (CTCs) after treatment has imp
Autor:
Yeung-Chul Mun, James Larkin, Keith T. Flaherty, Edward McKenna, Brigitte Dréno, Qian Zhu, Antoni Ribas, Axel Hauschild, Paolo A. Ascierto, Karl D. Lewis, Grant A. McArthur
Publikováno v:
JAMA Oncology. 4:1382
Importance Prognostic models may provide insight into clinical trial results and inform the clinical management of patients withBRAFV600–mutated metastatic melanoma. Objective To identify subgroups with distinct survival outcomes based on clinical
Autor:
Jason Gotlib, Anita Szoke, Jack W. Singer, Mark Drummond, Robert Daly, Srdan Verstovsek, Ronald Hoffman, Vikas Gupta, Claire N. Harrison, John Mascarenhas, Moshe Talpaz, Ruben A. Mesa, Suliman Al-Fayoumi, Aaron T. Gerds, Brady L. Stein, Tanya Granston, Jennifer A. Callahan, Catriona Jamieson, Alexander Pristupa
Publikováno v:
JAMA Oncology. 4:652
Importance Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib. Objective
Publikováno v:
JAMA Oncology. 4:573
Publikováno v:
JAMA Oncology. 4:263